The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
The Lancet - Early Online Publication,  Evidence Based Medicine  Clinical Article

In individuals with 5–year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. This benefit greatly exceeds any known hazards of statin therapy. Under present guidelines, such individuals would not typically be regarded as suitable for LDL–lowering statin therapy. The present report suggests, therefore, that these guidelines might need to be reconsidered.

Methods
  • This meta–analysis included individual participant data from 22 trials of statin versus control (n=134537; mean LDL cholesterol difference 1.08 mmol/L; median follow–up 4.8 years) and five trials of more versus less statin (n=39612; difference 0.51 mmol/L; 5.1 years).
  • Major vascular events were major coronary events (ie, non–fatal myocardial infarction or coronary death), strokes, or coronary revascularisations.
  • Participants were separated into five categories of baseline 5–year major vascular event risk on control therapy (no statin or low–intensity statin) (<5%, ≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in each, the rate ratio (RR) per 1.0 mmol/L LDL cholesterol reduction was estimated.

Results
  • Reduction of LDL cholesterol with a statin reduced the risk of major vascular events (RR 0.79, 95% CI 0.77–0.81, per 1.0 mmol/L reduction), largely irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all–cause mortality.
  • The proportional reduction in major vascular events was at least as big in the two lowest risk categories as in the higher risk categories (RR per 1.0 mmol/L reduction from lowest to highest risk: 0.62 [99% CI 0.47–0.81], 0.69 [99% CI 0.60–0.79], 0.79 [99% CI 0.74–0.85], 0.81 [99% CI 0.77–0.86], and 0.79 [99% CI 0.74–0.84]; trend p=0.04), which reflected significant reductions in these two lowest risk categories in major coronary events (RR 0.57, 99% CI 0.36–0.89, p=0.0012, and 0.61, 99% CI 0.50–0.74, p<0.0001) and in coronary revascularisations (RR 0.52, 99% CI 0.35–0.75, and 0.63, 99% CI 0.51–0.79; both p<0.0001).
  • For stroke, the reduction in risk in participants with 5–year risk of major vascular events lower than 10% (RR per 1.0 mmol/L LDL cholesterol reduction 0.76, 99% CI 0.61–0.95, p=0.0012) was also similar to that seen in higher risk categories (trend p=0.3).
  • In participants without a history of vascular disease, statins reduced the risks of vascular (RR per 1.0 mmol/L LDL cholesterol reduction 0.85, 95% CI 0.77–0.95) and all–cause mortality (RR 0.91, 95% CI 0.85–0.97), and the proportional reductions were similar by baseline risk.
  • There was no evidence that reduction of LDL cholesterol with a statin increased cancer incidence (RR per 1.0 mmol/L LDL cholesterol reduction 1.00, 95% CI 0.96–1.04), cancer mortality (RR 0.99, 95% CI 0.93–1.06), or other non–vascular mortality.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 Precautionary labelling of foods for allergen content: Are we ready for a global framework? Full Text World Allergy Organization Journal, May 8, 2014    Free full text    Review Article

2 A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: Sorafenib for second line renal cell cancer Full Text Cost Effectiveness and Resource Allocation, May 5, 2014    Free full text

3 New cholesterol guideline: LDL goals take backseat to statins Full Text American Pharmacists Association News, November 15, 2013    Free full text    Clinical Guideline

4 Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications Full Text Journal of Pharmacy and Pharmaceutical Sciences, January 3, 2014    Free full text    Clinical Article

5 Bedtime aspirin may be more beneficial for heart patients Full Text Pharmacy Times, December 2, 2013    Free full text    Clinical Article

6 Are chromium supplements helpful in lowering blood sugar levels? Full Text EurekAlert!, April 10, 2014    Free full text

7 Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents Expert Opinion on Pharmacotherapy, March 17, 2014    Review Article

8 Beyond statins: new lipid lowering strategies to reduce cardiovascular risk Current Atherosclerosis Reports, May 21, 2014    Review Article    Clinical Article

9 Efficacy and tolerability of carbamazepine for the treatment of painful diabetic neuropathy in adults: a 12-week, open-label, multicenter study Full Text International Journal of General Medicine, July 21, 2014    Free full text    Clinical Article

10 Unexpected results in cancer drug trial Full Text EurekAlert!, April 9, 2014    Free full text

11 Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: Clinical and economic consequences PharmacoEconomics, February 11, 2014    Clinical Article

12 Cost-effectiveness of cranberries vs antibiotics to prevent urinary tract infections in premenopausal women: a randomized clinical trial PLOS ONE, April 15, 2014    Review Article

13 HPV eradicated by AHCC supplement, preclinical study suggests Full Text EurekAlert!, March 24, 2014    Free full text

14 A systematic review: Can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clinical Infectious Diseases, July 25, 2014    Clinical Article

15 Vancomycin, metronidazole, or tolevamer for clostridium difficile infection: Results from two multinational, randomized, controlled trials Clinical Infectious Diseases, June 6, 2014    Clinical Article

16 Prescribing of high-dose acetaminophen products discouraged Full Text U.S. Pharmacist, March 11, 2014    Free full text    Clinical Article

17 Impact of a new method of warfarin management on patient satisfaction, time, and cost Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, August 23, 2013    Clinical Article

18 Clever chemistry improves a new class of antibiotics Full Text EurekAlert!, January 20, 2014    Free full text

19 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

20 Beta-lactam allergy: Clinical implications and costs Full Text Clinical and Molecular Allergy , December 4, 2013    Free full text    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close